Clinical Trials Browser

Phase 1/2 × Triple Negative Breast Neoplasms × pirfenidone × Clear all

NCT07161791 2025-09-09

Camrelizumab, Pirfenidone, and Chemotherapy in the Treatment of Advanced Triple-Negative Breast Cancer

Phase 1/2 Not yet recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms